News | September 18, 2012

Rising Cost of Inpatient Care Linked to Medical Devices, Not Imaging

Supplies and devices, such as stents, accounted for the largest proportion of hospital inpatient cost increases between 2001 and 2006.

MRI Systems Clinical Trial/Study Stents Cath Lab Health Service Research

September 18, 2012 — Inpatient hospital treatment accounts for the largest proportion of healthcare spending in the United States, with the use of diagnostic imaging services such as magnetic resonance images (MRIs) frequently implicated as the probable cause. A new analysis finds that the biggest expense may not be from imaging technology, but from supplies including medical devices, such as stents and artificial joints.

“One of the takeaway messages for hospitals is that they should examine their own data in closer detail to explore the costs that are rapidly rising and have a better understanding for the underlying reasons,” said lead author Jared Lane Maeda, Ph.D., of Truven Health Analytics in Washington, D.C.

The study — released in Health Services Research — used the 2001 and 2006 Healthcare Cost and Utilization Project State Inpatient Databases and Medicare Cost Reports for community, non-rehabilitation hospitals in nine states. The researchers conducted a cost analysis on more than 10.2 million patient discharges for various conditions.

At 24.2 percent of costs, “supplies and devices,” (defined as the “supply items required for patient care”) were the leading contributors to the increase in average cost per discharge. Intensive care unit charges contributed 17.6 percent, and room and board for a semi-private room was 11.3 percent. Imaging, such as computed tomography (CT) scans, and other advanced technological services contributed just 4.9 percent. The significant growth in the mean cost per discharge of supplies and devices suggests they should be examined more closely.

Caroline Steinberg, vice president of Trends Analysis for the American Hospital Association, said the group supports comparative effectiveness research to determine whether new drugs and devices are both clinically and cost effective. “This is an area where more research is needed,” she added. “And as for increased use of the intensive care unit, that is consistent with the trend towards older and sicker patients.”

Maeda added that payers might consider negotiating discounts in areas of care and cost that are growing quickly.

For more information: http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1475-6773/


Related Content

News | Cardiovascular Clinical Studies

May 1, 2024 — A study in more than 3,000 US counties, with 315 million residents, has suggested that air pollution is ...

Home May 01, 2024
Home
News | Cardiovascular Clinical Studies

April 30, 2024 — Regenerative heart therapies involve transplanting cardiac muscle cells into damaged areas of the heart ...

Home April 30, 2024
Home
News | Cardiovascular Clinical Studies

April 24, 2024 —Hello Heart, a digital leader in preventive heart health, today announced results from its latest study ...

Home April 24, 2024
Home
News | Cardiovascular Clinical Studies

April 22, 2024 — Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, welcomes the ...

Home April 22, 2024
Home
News | Cardiovascular Clinical Studies

April 16, 2024 — CVRx, Inc., a commercial-stage medical device company, announced today the availability of additional ...

Home April 16, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — Transcatheter aortic valve replacement (TAVR) was found to bring no increased risks and was associated ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 11, 2024 — People with a buildup of fatty atherosclerotic plaque in the heart’s arteries considered at risk of ...

Home April 11, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — Patients who took an angiotensin-converting enzyme (ACE) inhibitor while undergoing cancer treatment ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes ...

Home April 09, 2024
Home
News | Cardiovascular Clinical Studies

April 9, 2024 — The investigational drug ninerafaxstat showed a good tolerability and safety profile, along with ...

Home April 09, 2024
Home
Subscribe Now